Chetomin, a Hsp90/HIF1α pathway inhibitor, effectively targets lung cancer stem cells and non-stem cells

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.21262.
   PubMed Web of Science ®Google Scholar
• Schrank Z, Chhabra G, Lin L, Iderzorig T, Osude C, Khan N, Kuckovic A, Singh S, Miller R, Puri N, et al. Current molecular-targeted therapies in NSCLC and their mechanism of resistance. Cancers. 2018;10(7):224. doi:10.3390/cancers10070224.
   PubMed Web of Science ®Google Scholar
• El Rassy E, Botticella A, Kattan J, Le Péchoux C, Besse B, Hendriks L. Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment. Cancer Treat Rev. 2018;68:69–79. doi:10.1016/j.ctrv.2018.05.015.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Tan C-S, Gilligan D, Pacey S. Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol. 2015;16(9):e447–e59. doi:10.1016/S1470-2045(15)00246-6.
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8(10):755. doi:10.1038/nrc2499.
   PubMed Web of Science ®Google Scholar
• Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013;15(4):338. doi:10.1038/ncb2717.
   PubMed Web of Science ®Google Scholar
• Jego G, Hazoumé A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2013;332(2):275–285. doi:10.1016/j.canlet.2010.10.014.
   PubMed Web of Science ®Google Scholar
• Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010;11(7):515. doi:10.1038/nrm2918.
   PubMed Web of Science ®Google Scholar
• Wu Y, Huang B, Liu Q, Liu Y. Heat shock protein 90-β over-expression is associated with poor survival in stage I lung adenocarcinoma patients. Int J Clin Exp Pathol. 2015;8:8252.
   PubMedGoogle Scholar
• Ruiz MIG, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, Jassem E, Niklinski J, Muley T, van Zandwijk N, et al. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. PLoS One. 2008;3(3):e0001722. doi:10.1371/journal.pone.0001722.
   PubMed Web of Science ®Google Scholar
• Fan G-C. 2012. Role of heat shock proteins in stem cell behavior. In: Progress in molecular biology and translational science. Elsevier; 2012. p. 305–322. doi:10.1016/B978-0-12-398459-3.00014-9. Review.
   Google Scholar
• Isaacs JS, Xu W, Neckers L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell. 2003;3(3):213–217. doi:10.1016/S1535-6108(03)00029-1.
   PubMed Web of Science ®Google Scholar
• Modi S, Stopeck AT, Linden HM, Solit DB, Chandarlapaty S, Rosen N, D’Andrea G, Dickler M, Moynahan ME, Sugarman S, et al. HSP90 inhibition is effective in breast cancer: a phase 2 trial of tanespimycin (17AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011;17(15):5132–5139. clincanres. 0072.2011. doi:10.1158/1078-0432.CCR-11-0072
   PubMed Web of Science ®Google Scholar
• Akram A, Khalil S, Halim SA, Younas H, Iqbal S, Mehar S. Therapeutic uses of HSP90 inhibitors in non-small cell lung carcinoma (NSCLC). Curr Drug Metab. 2018;19(4):335–341. doi:10.2174/1389200219666180307122441.
   PubMed Web of Science ®Google Scholar
• Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18(1):64–76. doi:10.1158/1078-0432.CCR-11-1000.
   PubMed Web of Science ®Google Scholar
• Xu G-B, He G, Bai -H-H, Yang T, Zhang G-L, Wu L-W, Li G-Y. Indole Alkaloids from Chaetomium globosum. J Nat Prod. 2015;78(7):1479–1485. doi:10.1021/np5007235.
   PubMed Web of Science ®Google Scholar
• Oh SH, Woo JK, Jin Q, Kang HJ, Jeong JW, Kim KW, Hong WK, Lee H-Y. Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. Int J Cancer. 2008;122(1):5–14. doi:10.1002/ijc.23075.
   PubMed Web of Science ®Google Scholar
• Min H-Y, Yun HJ, Lee J-S, Lee H-J, Cho J, Jang H-J, Park S-H, Liu D, Oh S-H, Lee JJ, et al. Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer. 2015;14(1):113. doi:10.1186/s12943-015-0392-3.
   PubMedGoogle Scholar
• Ciocca DR, Arrigo AP, Calderwood SK. Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update. Arch Toxicol. 2013;87:19–48.
   PubMed Web of Science ®Google Scholar
• Fridlender M, Kapulnik Y, Koltai H. Plant derived substances with anti-cancer activity: from folklore to practice. Front Plant Sci. 2015;6:799. doi:10.3389/fpls.2015.00799.
   PubMed Web of Science ®Google Scholar
• Sznarkowska A, Kostecka A, Meller K, Bielawski KP. Inhibition of cancer antioxidant defense by natural compounds. Oncotarget. 2017;8(9):15996. doi:10.18632/oncotarget.13723.
   PubMedGoogle Scholar
• Leite ML, da Cunha NB, Costa FF. Antimicrobial peptides, nanotechnology, and natural metabolites as novel approaches for cancer treatment. Pharmacol Ther. 2018 Mar;183:160–176. doi: 10.1016/j.pharmthera.2017.10.010. Epub 2017 Oct 10. Review.
   PubMed Web of Science ®Google Scholar
• Marmouzi I, Faouzi MEA, Saidi N, Cherrah Y, Rehberg N, Ebada SS, Ebrahim W, Kalscheuer R, Proksch P. Bioactive secondary metabolites from chaetomium globosum, an endophyte from the moroccan plant avena sativa. Chem Nat Compd. 2017;53(6):1208–1211. doi:10.1007/s10600-017-2242-6.
   Web of Science ®Google Scholar
• Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001;410(6832):1111–1116. doi:10.1038/35074129.
   PubMed Web of Science ®Google Scholar
• Staab A, Loeffler J, Said HM, Diehlmann D, Katzer A, Beyer M, Fleischer M, Schwab F, Baier K, Einsele H, et al. Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC Cancer. 2007;7(1):213. doi:10.1186/1471-2407-7-213.
   PubMedGoogle Scholar
• Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004;6(1):33–43. doi:10.1016/j.ccr.2004.06.009
   PubMed Web of Science ®Google Scholar
• Le HT, Nguyen HT, Min H-Y, Hyun SY, Kwon S, Lee Y, Le THV, Lee J, Park JH, Lee H-Y, et al. Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells. Cancer Lett. 2018;412:297–307. doi:10.1016/j.canlet.2017.10.013.
   PubMed Web of Science ®Google Scholar
• Kim J-H, Choi DS, Lee O-H, Oh S-H, Lippman SM, Lee H-Y. Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. Blood. 2011 Sep 1; 118(9):2622–31. doi: 10.1182/blood-2010-08-299784.
   Web of Science ®Google Scholar
• Lee S-C, Min H-Y, Choi H, Bae SY, Park KH, Hyun SY, Lee HJ, Moon J, Park S-H, Kim JY, et al. Deguelin analogue SH-1242 inhibits Hsp90 activity and exerts potent anticancer efficacy with limited neurotoxicity. Cancer Res. 2016;76(3):686–699. doi:10.1158/0008-5472.CAN-15-1492.
   PubMed Web of Science ®Google Scholar
• Abdullah LN, Chow EK-H. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2(1):3. doi:10.1186/2001-1326-2-3.
   PubMedGoogle Scholar
• Xu X, Chai S, Wang P, Zhang C, Yang Y, Yang Y, Wang K. Aldehyde dehydrogenases and cancer stem cells. Cancer Lett. 2015;369(1):50–57. doi:10.1016/j.canlet.2015.08.018.
   PubMed Web of Science ®Google Scholar
• Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82(2):179–189. doi:10.1016/j.lungcan.2013.07.025.
   PubMed Web of Science ®Google Scholar
• Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet. 2008;40(5):600. doi:10.1038/ng.115.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW. p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev. 2010;24(13):1389–1402. doi:10.1101/gad.1940710.
   PubMed Web of Science ®Google Scholar
• Boo H-J, Min H-Y, Jang H-J, Yun HJ, Smith JK, Jin Q, Lee H-J, Liu D, Kweon H-S, Behrens C, et al. The tobacco-specific carcinogen-operated calcium channel promotes lung tumorigenesis via IGF2 exocytosis in lung epithelial cells. Nat Commun. 2016;7(1):12961. doi:10.1038/ncomms12961.
   PubMedGoogle Scholar
• Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275–291. doi:10.1016/j.stem.2014.02.006.
   PubMed Web of Science ®Google Scholar
• Antonsson C, Whitelaw ML, McGuire J, J-A G, Poellinger L. Distinct roles of the molecular chaperone hsp90 in modulating dioxin receptor function via the basic helix-loop-helix and PAS domains. Mol Cell Biol. 1995;15(2):756–765. doi:10.1128/MCB.15.2.756.
   PubMed Web of Science ®Google Scholar
• Minet E, Mottet D, Michel G, Roland I, Raes M, Remacle J, Michiels C. Hypoxia‐induced activation of HIF‐1: role of HIF‐1α‐Hsp90 interaction. FEBS Lett. 1999;460(2):251–256. doi:10.1016/S0014-5793(99)01359-9.
   PubMed Web of Science ®Google Scholar
• Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013;13(10):727. doi:10.1038/nrc3597.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK. Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res. 2005;11:3385–3391.
   PubMed Web of Science ®Google Scholar
• Dewangan J, Srivastava S, Mishra S, Pandey PK, Divakar A, Rath SK. Chetomin induces apoptosis in human triple-negative breast cancer cells by promoting calcium overload and mitochondrial dysfunction. Biochem Biophys Res Commun. 2018;495(2):1915–1921. doi:10.1016/j.bbrc.2017.11.199.
   PubMed Web of Science ®Google Scholar
• Viziteu E, Grandmougin C, Goldschmidt H, Seckinger A, Hose D, Klein B, Moreaux J. Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma. Br J Cancer. 2016;114(5):519. doi:10.1038/bjc.2016.20.
   PubMed Web of Science ®Google Scholar